SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD), a pioneer in developing medical devices to treat infectious disease, disclosed today it has filed a provisional patent entitled, “Affinity Capture of Circulating Cancer Biomarkers,” with the U.S. Patent and Trademark Office (USPTO). The patent describes the use of the Aethlon Hemopurifier® as a device that fills the unmet need of identifying circulating cancer biomarkers to assist in early detection of cancer, monitor cancer treatment, and detect cancer recurrence. The blood represents a rich source of cancer biomarkers, as tumors secrete exosomes and shed other macromolecules and cellular components that reach the bloodstream. The Hemopurifier® addresses the previous challenge of isolating and identifying low-abundant cancer biomarkers from the complex mixture of substances contained in blood.
